Open Label, Randomized, Parallel Group, Single Dose, 2-Way Comparison Bioequivalence Study of Certolizumab Pegol Solution Injected Either by a Pre-Filled Syringe (Reference) or by an Auto Injection Device (Test) to Healthy Volunteers.

Trial Profile

Open Label, Randomized, Parallel Group, Single Dose, 2-Way Comparison Bioequivalence Study of Certolizumab Pegol Solution Injected Either by a Pre-Filled Syringe (Reference) or by an Auto Injection Device (Test) to Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2016

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors UCB
  • Most Recent Events

    • 20 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top